The scientific focus adapted
to express the optimum potential
of your molecule

Marketing:
Unparalleled vision in metabolic disorders and risk assessment expertise for post-marketing studies and drug repositioning.

HeartArteryMacrophageLiverMusclePancreasAdipose Tissue

Preclinical development:
In-house predictive models and tracer technologies enable the generation of Proof of Concept efficacy data for your drugs.

Discovery:
Screening and lead validation utilize a dedicated research platform which combine with our focused scientific vision.

Home > News > Physiogenex will present the effects of obeticholic acid in its novel Diet-Induced NASH (DIN) hamster model at the Keystone Symposium on Bile Acid Receptors as Signal Integrators in Liver and Metabolism, in Monterey, CA, USA, March 3-7, 2017.

News detail

Return to all news & events

02/28/2017 Physiogenex will present the effects of obeticholic acid in its novel Diet-Induced NASH (DIN) hamster model at the Keystone Symposium on Bile Acid Receptors as Signal Integrators in Liver and Metabolism, in Monterey, CA, USA, March 3-7, 2017.

Unlike rats and mice, the DIN hamster has a closer lipid/lipoprotein metabolism as compared to humans. In fact, it replicates the LDL increase and HDL lowering induced by obeticholic acid, as observed in clinical trials.

This unique model to evaluate drugs targeting NASH will be presented by Dr. François Briand, Director of Research and Business Development at Physiogenex, during the poster session on Saturday March the 4th, 2017.

If you want to set an appointment during this Keystone Symposium with Dr. François Briand and/or discuss about our NASH models, please contact us!